UNSPSC 51434006: Bepridil hydrochloride

This classification denotes a calcium channel blocker with the molecular formula C24H34N2O.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4W2P15D93M, chemically known as 1-pyrrolidineethanamine, beta-((2-methylpropoxy)methyl)-n-phenyl-n-(phenylmethyl)-, monohydrochloride but more generally known as bepridil hydrochloride, which bears US NIH Compound Identifier 50088. European Medicines Agency schedules Bepridil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13042MIG.

UNSPSC 51434006 Bepridil hydrochloride, a Commodity code, covers pharmaceutical active ingredients and finished medications procured by state and local emergency services, health agencies, and cooperative purchasing consortia for clinical and emergency medical use. State and local governments buying under this code solicit individual medications or bundled pharmaceutical lots for emergency medical services, hospital systems, and public health programs. The issuing bodies include municipal fire departments and emergency services, state health and human services agencies, and multistate cooperative purchasing alliances. Recent solicitations show governments procuring advanced life support medications, generic pharmaceuticals, and over-the-counter products in quantities ranging from hundreds to thousands of units, with firm pricing, expiration-date warranties, and supply-chain compliance documentation (cGMP, DSCSA, OSHA Safety Data Sheets) as standard requirements. Small local business enterprise set-asides and accessibility documentation (WCAG 2.2 Level AA, Section 508) appear in current municipal requests.

Activity is present across multiple states. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 for advanced life support medications including labetalol, epinephrine, adenosine, and diltiazem—4,530 total units with a $40,000 estimated value and a 5 percent SLBE bid discount—due April 8, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities, including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued an exploratory RFI in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program before issuing a formal competitive solicitation. Municipal emergency services and state cooperative purchasing groups are the primary buying volume; geographic activity is concentrated in Texas, Minnesota, Oregon, and Florida.